2016
ACoP7, Bellevue, WA, US
Mechanistic approach to describe multiple effects of regulatory molecules on cell dynamics process in immune response
Authors: Oleg Demin, Evgeny Metelkin, Galina Lebedeva, Sergey Smirnov
Quantitative systems pharmacology model of amyloid pathology allows for clinical endpoint prediction and hypothesis testing
Authors: Tatiana Karelina1, Oleg Demin1, Timothy Nicholas2, Sridhar Duvvuri2
Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
Exploration of differences between mechanism-based PK/PD and systems pharmacology models
Authors: Oleg Demin
Modeling of immune response suppression by hepatitis C virus and nivolumab treatement in chronic hepatitis C patients using quantitative systems pharmacology approach
Authors: Oleg Demin Jr
PAGE 2016, Lisboa, Portugal
Population PK modeling of RPH-104, novel optimized IL-1 beta trap, and assessment of the immunogenicity effect on pharmacokinetics
Authors: Evgeny Metelkin1, Tatiana Petukhova1, Oleg Demin1, Elena Shipaeva2, Mikhail Samsonov2, Anna Krotkova2, Yan Lavrovsky3
Affiliation: 1InSysBio, Moscow, Russia; 2JSC R-Pharm, Moscow, Russia; 3R-Pharm Overseas, Inc., San Diego, US
The International Liver Congress 2016, Barcelona, Spain
Quantitative Systems Pharmacology model of Hepatitis C: Prediction of Results of Ongoing Clinical Trials of Direct Antiviral Agents Combination Therapies
Authors: Oleg Demin Jr
ASCPT 2016, San Diego, CA, US
Analysis of brain pharmacodynamics of gamma-secretase inhibitors using quantitative translational systems pharmacology model
Authors: Tatiana Karelina1, Oleg Demin1, Timothy Nicholas2, Sridhar Duvvuri2
Affiliation: 1InSysBio, Moscow, Russia; 2Pfizer Worldwide R&D, Groton, CT, USA
Population modeling study for evaluation of effective and safe dose of RPH-104 for the treatment of Behcet’s syndrome and FMF
Authors: Evgeny Metelkin1, Tatiana Petukhova1, Oleg Demin1, Elena Shipaeva2, Mikhail Samsonov2, Anna Krotkova2, Yan Lavrovsky3
Affiliation: 1InSysBio, Moscow, Russia; 2JSC R-Pharm, Moscow, Russia; 3R-Pharm Overseas, Inc., San Diego, US
Systems Pharmacology Model Of Hepatitis C: Exploration Of Effect Of Combinations Of Direct Antiviral Agents On HCV Production During Treatment Of HCV Patients
Authors: Oleg Demin Jr, Oleg Demin
Population modeling and simulation of RPH-203 effects in the context of prevention of skeletal-related events in patients with bone metastases
Authors: Evgeny Metelkin1, Tatiana Petukhova1, Oleg Demin1, Shorena Archuadze2, Galina Konopleva2, Dmitry Koloda2, Mikhail Samsonov2
Affiliation: 1InSysBio, Moscow, Russia; 2JSC R-Pharm, Moscow, Russia
2015
ASCPT 2015, New Orleans, LA, US
Systems Pharmacology Modeling of Hypomethylating agents Decitabine and SGI-110 for Evaluation of AML treatment by targeting the S-phase with prolonged Pharmacokinetic exposures
Authors: Aram Oganesian, Oleg Demin Jr, Antonina Nikitich, Oleg Demin and Mohammad Azab
Affiliation: Astex Pharmaceuticals Inc., Dublin, CA, US; 2InSysBio, Moscow, Russia
20th Congress of EHA, Vienna, Austria
Application of Systems Pharmacology Modeling for Evaluation of Therapies Effect on Blast Dynamics in Acute Lymphoblastic Leukemia
Authors: Antonina Nikitich, Oleg Demin Jr
First
Prev